Shandong Anshun Pharmaceutical Co., Ltd.November 16, 2020

FDA 483 - Shandong Anshun Pharmaceutical Co., Ltd. - November 16, 2020

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Shandong Anshun Pharmaceutical Co., Ltd.

Record Details

An FDA inspection of Shandong Anshun Pharmaceutical Co., Ltd., an API manufacturer in China, revealed significant issues with their quality control systems. The firm failed to follow its written stability program, resulting in stability tests not being performed by their planned due dates. Additionally, analysts in the QC Laboratory were found to be inadequately trained on analytical methods, leading to out-of-specification results due to analyst error.

Company: Shandong Anshun Pharmaceutical Co., Ltd.
Inspection Date: November 16, 2020
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Marcus A. Ray (Supervisory Consumer Safety Officer, China Office)

Open in Dashboard

ID · fe9359f5-0288-407b-861c-6f57da18fbe8